LoginRegister

    Roche wins Japan approval for personalised cancer drug Rozlytrek

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  

    ZURICH: Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world's biggest maker of cancer drugs pushes ahead in personalised medicines that require a biomarker test to identify prospective patients.


    Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases.

    Read Also: Roche appoints Thomas Schinecker as new head of $13 billion diagnostics unit
    biomarkercancercancer drug Rozlytrekentrectinibjapan approvalNTRKRocheSwiss drugmaker Roche
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      sidekick